Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer
Several lines of preclinical evidence indicate that combining PI3K and CDK4/6 inhibitors may further enhance the efficacy of hormonal therapy by overcoming de novo and acquired resistance to PI3K and CDK4/6 blockade. We evaluated the combination of abemaciclib, letrozole and LY3023414 (an orally ava...
Saved in:
Main Authors: | Panagiotis A. Konstantinopoulos (Author), Niya Xiong (Author), Carolyn Krasner (Author), Joyce F. Liu (Author), Hannah Sawyer (Author), Madeline Polak (Author), Hope Needham (Author), Megan Geddes (Author), Lani Koppermann (Author), Meghan Shea (Author), Cesar Castro (Author), Su-Chun Cheng (Author), Ursula A. Matulonis (Author), Elizabeth K. Lee (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC
by: Dongcheng Liu, et al.
Published: (2022) -
Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
by: Chao-Yue Sun, et al.
Published: (2022) -
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
by: Corona SP, et al.
Published: (2018) -
Estrogen/androgen balance in men with hyperestrogenism normalized by using letrozole of the aromatase inhibitor drug class
by: Z. Sh. Pavlova, et al.
Published: (2022) -
Clinical use of Abemaciclib a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with breast cancer - literature review
by: Katarzyna Maria Krukar, et al.
Published: (2024)